冷循环射频消融术治疗原发性肝癌患者疗效及外周血Treg细胞的变化观察

doi:10.3969/j.issn.1672-5069.2021.01.032

摘要/Abstract

摘要： 目的探讨采用冷循环射频消融术治疗原发性肝癌(PLC)患者的疗效及对外周血调节性T细胞(Treg)的影响。方法 2018年4月～2019年4月我院收治的PLC患者94例,随机分为射频消融治疗组47例和经肝动脉化疗栓塞术(TACE)治疗47例,分别使用TM-RFTI1型冷循环射频消融系统行视频消融或采用碘化油与表柔比星混悬乳液或明胶海绵化疗栓塞。使用FACSCalibur流式细胞仪检测外周血调节性T细胞(Treg)百分比。结果在治疗后3个月评估,射频消融治疗组完全缓解、部分缓解和疾病稳定发生率分别为42.6%、40.4%和6.4%,疾病控制率为89.4%,显著高于TACE治疗组【分别为31.9%、27.7%、12.8%和72.3%,P＜0.05】;治疗前,射频消融治疗组血清ALT、ALP、TBIL和外周血Treg细胞百分比分别为(96.4±22.4)U/L、(184.5±30.5)U/L、(18.5±5.8)μmol/L和9.5±1.5)%,与TACE组比,无统计学差异,治疗后,射频消融治疗组血清ALT和ALP及外周血Treg细胞百分比分别为(35.1±5.8)U/L、(84.5±15.8)U/L和(6.2±0.5)%,显著低于TACE治疗组;射频消融术后腹胀、腹泻、腹腔感染、发热和消化道出血等并发症发生率为8.5%,显著低于TACE治疗的25.5%,差异有统计学意义(P＜0.05)。结论在彩超引导下采用冷循环射频消融治疗PLC患者可提高短期临床治疗效果,降低Treg细胞百分比,对肝功能的影响比较小,值得进一步临床研究。

关键词: 原发性肝癌, 冷循环, 射频消融, 外周血调节性T细胞, 治疗

Abstract: Objective The aim of this study was to investigate the short-term efficacy of radiofrequency ablation (RFA) with cold circulation in the treatment of patients with primary liver cancer (PLC) and the change of peripheral blood fegulatory T cells (Treg). Methods A total of 94 patients with PLC were admitted to our hospital between April 2018 and April 2019, and were randomly divided into observation group (n=47) and control group (n=47). The patients in the control group received hepatic artery chemoembolization (TACE), while those in the observation group received RFA with cold circulation under the guidance of color ultrasound. The percentages of peripheral blood Treg cells were detected by TCM. Results At the end of three month after operation, the complete response, partial response and disease stable rates in the RFA-treated patients were 42.6%,40.4% and 6.4%, and the disease control rate was 89.4%, all significantly higher than (31.9%, 27.7%, 12.8%, and 72.3%, P＜0.05】 in TACE-treated patients except for disease stable rate; at presentation, serum ALT, ALP, total bilirubin and the percentage of peripheral blood cells in RFA-treated patients were (96.4±22.4)U/L, (184.5±30.5)U/L,(18.5±5.8)μmol/L and 9.5±1.5)%, not significantly different compared to in TACE-treated patients, while serum ALT, ALP and percentage of peripheral blood Treg cells in RFA-treated patients were (35.1±5.8)U/L,(84.5±15.8)U/L and (6.2±0.5)% after operation, all significantly lower than in TACE-treated patients; the incidence of post operation complications such as abdominal distension, diarrhea, peritonitis, fever and gastrointestinal bleeding was 8.5%, significantly lower than 25.5% (P＜0.05)in TACE-treated group.Conclusion The application of RFA with cold circulation under color ultrasound guidance in treatment of patients with PLC could get excellent short-term efficacy, which might reduce peripheral blood Treg cells, and has a higher safety.

Key words: Hepatoma, Cold recycling, Radiofrequency ablation, Peripheral blood Treg cells, Therapy

李亚敏, 王瑞婷, 王瑛瑛. 冷循环射频消融术治疗原发性肝癌患者疗效及外周血Treg细胞的变化观察[J]. 实用肝脏病杂志, 2021, 24(1): 123-126.

Li Yamin, Wang Ruiting, Wang Yingying. Short-term efficacy of radiofrequency ablation with cold circulation in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2021, 24(1): 123-126.

参考文献

[1] Kudo M. Breakthroughs in the management of hepatocellular carcinoma: celebrating 50 years of the liver cancer study group of Japan. Oncology, 2014, 87(1):1-6.
[2] Malki A, El-Sharkawy A, EL-Sayed M, et al. Antitumor activities of the novel isosteviol derivative 10c against liver cancer. Anticancer Res, 2017, 37(4):1591-1601.
[3] Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer, 2016, 139(7):1534-1545.
[4] Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology, 2018, 67(2):600-611.
[5] Nakashima T, Okuda K, Kojiro M, et al. Primary liver cancer coincident with schistosomiasis Japonica. a study of 24 necropsies. Cancer, 1975, 36(4):1483-1489.
[6] Zhao H, Liu F, Yue Z, et al. Association of hepatic vein lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death. J Int Medical Res, 2017, 45(3):1148-1157.
[7] Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer, 2010, 116(5):1305-1314.
[8] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6):929-946.
[9] Riaz A, Memon K, Miller FH, et al. Role of EASL, RECIST and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol, 2011, 54(4):695.
[10] 李靖, 朱文良, 康鑫鑫, 等. 经肝动脉化疗栓塞联合射频消融治疗原发性肝癌的预后影响因素及预测模型. 中华肿瘤杂志, 2017, 39(10):787-791.
[11] 王秀清, 马艳君, 詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析. 实用肝脏病杂志, 2019, 22(2):260-263.
[12] Kim YS, Rhim H, Tae K, et al. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid, 2006, 16(4):361-367.
[13] Weusten BL, Bergman JJ. Cryoablation for managing Barret’s esophagus refractory to radiofrequency ablation? Don’t embrace the cold too soon! Gastrointest Endosc, 2015, 82(3):449-451.
[14] Liapi E, Geschwind JF. Chemoembolization for primary and metastatic liver cancer. Cancer J, 2010, 16(2):156-162.
[15] Imai N, Katano Y, Kuzuya T, et al. An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology, 2013, 60(125):965-970.
[16] Tait IS, Yong SM, Cuschieri SA. Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation. Br J Surg, 2002, 89(12):1613-1619.
[17] 张宝芳, 程明亮, 陆爽, 等. 替诺福韦及替比夫定对贵州地区不同基因型HBeAg阳性乙肝孕妇HBV RNA的影响. 中华医学杂志, 2018, 98(43):3503.
[18] Hira K, Tariq RM, Sultana V, et al. Effect of seaweeds occurring at Karachi coast on mosquito larvae and liver function in rats. Pak J Pharm Sci, 2017, 30(2):387-391.
[19] 罗葆明, 杨焰, 智慧, 等. 射频消融术中二维声像图强回声区大小与消融范围的相关性研究. 中华超声影像学杂志, 2008, 17(2):130-132.
[20] Garrean S, Hering J, Saied A, et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg, 2008, 195(4):516-520.